Black women's cancer survival gap widens after year 5

In a SEER analysis of nearly 11 million US cancer survivors, Black women and American Indian/Alaska Native women had the poorest long-term survival among women, and by 15 years after diagnosis Black women were more than 25 percent more likely to die than White women (survival ratio 0.74, 95% CI 0.73 to 0.74) (Cheng et al., Cancer Medicine 2026, PMID 42092747). The deficit did not shrink as patients moved further from their diagnosis. It grew. The authors' conclusion names the pattern: survival disparities "persist and widen beyond 5 years post-diagnosis, particularly among non-Hispanic AI/AN individuals, NHPI men, and Black women" (Cheng et al., 2026).

A survival ratio is not a hazard ratio. It compares how a group survives against a White reference group over the same window, and a value below 1.0 means worse relative survival. The 0.74 figure for Black women at year 15 is what the study's authors translate, in plain language, as "approximately 25% lower survival than White females" (Cheng et al., 2026). The number is large, and the place it shows up is the part of the cancer timeline almost nobody is measuring.

Most cancer-disparity reporting stops at two numbers: how many people get a cancer, and how many are alive five years later. Five-year relative survival is the standard figure registries publish, and the Cheng team kept several of its own analyses at five years "to maintain comparability with prior literature" (Cheng et al., 2026). Five years is also where a patient is often told the words "no evidence of disease" and discharged from active oncology care into routine follow-up.

That hand-off matters more for some patients than others, because the survivor population is large and growing. The National Cancer Institute estimated 18.1 million cancer survivors living in the United States as of January 2022, a figure it projects will reach 26 million by 2040 (NCI, Cancer Statistics). Survivorship is now a decades-long phase of care for millions of people, not a footnote to treatment. The Cheng analysis is unusual because it followed survivors out to 15 years and asked whether the racial gap that is well documented at diagnosis and at five years holds, closes, or worsens in that long tail. For Black women, it worsened.

The study drew on 22 SEER registries covering cancers diagnosed from 2000 to 2021, a cohort of 10,894,683 survivors (Cheng et al., 2026). Black patients made up 10.9 percent of that cohort and women made up 49 percent, so the year-15 estimates for Black women rest on a large sample rather than a thin subgroup. Among women, Black survivors had the lowest survival across all five cancer sites the study examined, and two of those sites carry the disparity most clearly in the long tail.

Breast cancer is the clearest. By year 15, cancer death ran almost 20 percent higher among Black breast-cancer survivors than among White survivors (survival ratio 0.81, 95% CI 0.79 to 0.82) (Cheng et al., 2026). The deficit appears immediately after diagnosis for Black women and keeps widening through the entire 15-year follow-up. It never plateaus. That widening is measured a decade past the point where most survivors stop being actively followed for disparity.

Uterine (corpus) cancer is the largest of the five site-specific deficits the study measured in women: a survival ratio of 0.67 (95% CI 0.64 to 0.70) at year 15 for Black women, a 33 percent relative-survival gap that plateaus after roughly five years rather than closing (Cheng et al., 2026). Skin melanoma follows the same plateau shape (survival ratio 0.70 at year 15). The pattern across all cancers was sharpest in advanced disease: among Black women diagnosed with distant-stage cancers, the survival ratio was 0.75 (95% CI 0.73 to 0.77) at 10 years, a 25 percent relative deficit a full decade out. Advanced disease hit Black men in the long tail as well: Black men with distant-stage cancers were 35 percent more likely to die from cancer than White men by year 15 (survival ratio 0.65, 95% CI 0.60 to 0.70), against 5 percent for localized disease (Cheng et al., 2026).

One number from this study that has circulated in summary coverage does not belong to Black patients. The paper's prostate-cancer survival figure (a 12 percent higher death rate, survival ratio 0.88) describes Asian survivors, not Black men (Cheng et al., 2026). This analysis does not establish a Black prostate-cancer survival figure, and it should not be cited as one.

The most useful question a survivor can ask of a number like this is whether it is an access problem or a survivorship problem. If Black women are diagnosed later, at more advanced stages, that alone could explain worse survival, and the fix would sit upstream at screening and diagnosis. If the gap holds even among patients diagnosed at the same stage, the problem lives inside the survivorship years themselves.

The Cheng analysis was built to test the first explanation. The authors stratified their results by stage at diagnosis, restricting that analysis to the 8,365,162 cases diagnosed since 2004, and separately examined five-year survival by county-level income (Cheng et al., 2026). The disparity held within stage strata and persisted across counties at every income level; in the authors' words, these trends "are not solely explained by income or cancer stage." Whatever is driving the widening is not fully captured by when a Black woman's cancer is found or by the wealth of her ZIP code.

The honest limit of the study is what it cannot say. This was a relative-survival analysis reporting ratios, not a multivariable model that adjusts for insurance, treatment adherence, or comorbidity. SEER does not directly capture whether a survivor completed her recommended endocrine therapy, kept her surveillance imaging schedule, or carried a second chronic condition into her survivorship years. So the study documents the size and the persistence of the gap, and it rules out stage at diagnosis and county income as complete explanations. It does not isolate the cause. That distinction is the difference between a finding a reader can act on and a headline that overreaches.

One implication follows directly from the design. A strategy aimed only at catching Black women's cancers earlier would not close a gap that already survives adjustment for stage at diagnosis. On-time screening still matters upstream (our guides on colon cancer screening for Black adults and the widening lung cancer screening disparity cover that side), but the years of care that come after the diagnosis have to be part of the answer, which is exactly the stretch this study shows is going unmeasured.

Hui G. Cheng and colleagues at Virginia Commonwealth University's Massey Comprehensive Cancer Center, who conducted the analysis, framed the result as a measurement problem as much as a clinical one. Their conclusion states that survival disparities "persist and widen beyond 5 years post-diagnosis, particularly among non-Hispanic AI/AN individuals, NHPI men, and Black women," and points to "the need for long-term, risk-based and tailored survivorship care" (Cheng et al., Cancer Medicine 2026;15(5):e71919). The widening, in their data, was not an artifact of who started out sicker. It accumulated over the years that follow-up care is supposed to cover.

The practical reading for a Black survivor is that the survivorship years are not a victory lap. They are a stretch of care where surveillance, recurrence monitoring, and management of treatment side effects decide a meaningful share of long-term outcome, and where the racial gap is widest and least scrutinized.

The Cheng data points to the years after active treatment as the place to apply pressure. Two requests are concrete enough to bring to an oncology visit.

First, ask for a written survivorship care plan. The National Cancer Institute says a survivor should receive one from the oncologist or treatment team once treatment ends: a document that records the cancer diagnosis and treatments received, the specific late and long-term effects to watch for, and a follow-up schedule with named tests and intervals (NCI, Follow-Up Medical Care). If active treatment has ended and no one has handed over a written plan, request one and ask which clinician owns each item on the follow-up schedule. A verbal "come back in a year" is not a plan.

Second, ask who is monitoring you for recurrence and for treatment side effects, and on what calendar, through year 10 and beyond. For survivors who want a clinician who co-manages survivorship and understands these patterns, the blackhealth.org provider directory lists Black oncologists and primary-care physicians, with verified license and NPI on file, who treat Black patients and coordinate long-term follow-up. A survivorship plan is only useful if someone is accountable for keeping it. The directory is one way to find that someone.